GE17-1440-02
Ficoll® Paque Plus
Cytiva 17-1440-02, pack of 6 × 100 mL
Synonim(y):
Ficoll density gradient medium, cell culture media
Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
About This Item
Kod UNSPSC:
12352201
NACRES:
NA.25
Polecane produkty
Postać
liquid
opakowanie
pack of 6 × 100 mL
producent / nazwa handlowa
Cytiva 17-1440-02
kolor
Colorless to slightly yellow
zakres pH
5.5-7.5
Powiązane kategorie
Opis ogólny
Ficoll-Paque Plus is a recognized standard in laboratories worldwide for the isolation of human lymphocytes for in vitro studies.
Ficoll-Paque PLUS is a ready to use, sterile medium for isolation of lymphocytes in high yield from peripheral blood using a simple and rapid centrifugation procedure. It maintains the viability and a representative distribution of B and T lymphocytes.
Ficoll-Paque PLUS is a ready to use, sterile medium for isolation of lymphocytes in high yield from peripheral blood using a simple and rapid centrifugation procedure. It maintains the viability and a representative distribution of B and T lymphocytes.
Zastosowanie
For in vitro isolation of lymphocytes from human peripheral blood.
Cechy i korzyści
- Ready to use sterile medium for isolation of human lymphocytes in high yield from peripheral blood.
- Maintains viability and representative distribution of B and T lymphocytes.
- Low levels of endotoxin (< 0.12 EU/mL).
Przechowywanie i stabilność
Please be aware this product may be shipped 90 days before the expiration date. For more information on the batch specific expiration date, please contact technical service.
Store at 4 to 30 °C ()
Komentarz do analizy
To view the Certificate of Analysis for this product, please visit www.cytiva.com.
Informacje prawne
Ficoll is a registered trademark of Cytiva
This page may contain text that has been machine translated.
Hasło ostrzegawcze
Danger
Zwroty wskazujące rodzaj zagrożenia
Zwroty wskazujące środki ostrożności
Klasyfikacja zagrożeń
Flam. Liq. 2
Kod klasy składowania
3 - Flammable liquids
Klasa zagrożenia wodnego (WGK)
WGK 3
Certyfikaty analizy (CoA)
Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
Klienci oglądali również te produkty
Mehdi Hassanpour et al.
Stem cell research & therapy, 11(1), 139-139 (2020-03-29)
To date, many attempts are employed to increase the regenerative potential of stem cells. In this study, we evaluated the hypothesis of whether an autophagy modulation could alter differentiation potency of CD146+ cells into mature pericyte, endothelial, and cardiomyocyte lineage.
Matthew A Lakins et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 26(15), 4154-4167 (2020-04-30)
With the increased prevalence in checkpoint therapy resistance, there remains a significant unmet need for additional therapies for patients with relapsing or refractory cancer. We have developed FS222, a bispecific tetravalent antibody targeting CD137 and PD-L1, to induce T-cell activation
Jingyong Li et al.
Arteriosclerosis, thrombosis, and vascular biology, 39(3), 446-458 (2019-01-18)
Objective- Inflammation occurs during the progression of abdominal aortic aneurysm (AAA). IL (interleukin)-33 is a pleiotropic cytokine with multiple immunomodulatory effects, yet its role in AAA remains unknown. Approach and Results- Immunoblot, immunohistochemistry, and immunofluorescent staining revealed increased IL-33 expression
Hagen Schwenzer et al.
Cell reports, 26(12), 3416-3428 (2019-03-21)
In eukaryotes, tRNAs are transcribed in the nucleus and exported to the cytosol, where they deliver amino acids to ribosomes for protein translation. This nuclear-cytoplasmic movement was believed to be unidirectional. However, active shuttling of tRNAs, named tRNA retrograde transport
Rajan George et al.
Human vaccines & immunotherapeutics, 16(4), 779-792 (2019-11-07)
Chimigen® HBV Immunotherapeutic Vaccine (C-HBV), a recombinant chimeric fusion protein comprising hepatitis B virus (HBV) S1 and S2 surface antigen fragments, Core antigen and a murine monoclonal antibody heavy chain fragment (Fc), was designed and produced in Sf9 insect cells.
Protokoły
Ficoll 400® to niejonowy polimer o wysokiej hydrofilowości i rozpuszczalności w wodzie, odpowiedni do różnych zastosowań biologicznych.
Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.
Skontaktuj się z zespołem ds. pomocy technicznej